Difference between revisions of "Strep. Groups A, B, C, G"

(Antibiotic SensitivitiesSanford Guide to Antimicrobial Therapy 2010)
Line 40: Line 40:
 
| ||Meropenem||+
 
| ||Meropenem||+
 
|-
 
|-
| ||Aztreonam||0
+
| ||[[Aztreonam[[||0
 
|-
 
|-
 
| Fluroquinolones||Ciprofloxacin||+/-
 
| Fluroquinolones||Ciprofloxacin||+/-
Line 68: Line 68:
 
| ||Cefizoxime||+
 
| ||Cefizoxime||+
 
|-
 
|-
| ||CefTRIAXone||+
+
| ||[[CefTRIAXone]]||+
 
|-
 
|-
 
| ||Ceftobiprole||+
 
| ||Ceftobiprole||+
Line 80: Line 80:
 
| 1st G. Ceph||Cefadroxil||+
 
| 1st G. Ceph||Cefadroxil||+
 
|-
 
|-
| ||Cephalexin||+
+
| ||[[Cephalexin]]||+
 
|-
 
|-
 
| 2nd G. Ceph||Cefaclor/Loracarbef||+
 
| 2nd G. Ceph||Cefaclor/Loracarbef||+
Line 128: Line 128:
 
| ||Trimethoprim||+
 
| ||Trimethoprim||+
 
|-
 
|-
| ||TMP-SMX||+
+
| ||[[TMP-SMX]]||+
 
|-
 
|-
 
| Urinary Agents||Nitrofurantoin||+
 
| Urinary Agents||Nitrofurantoin||+
Line 136: Line 136:
 
| Other||Rifampin||+
 
| Other||Rifampin||+
 
|-
 
|-
| ||Metronidazole||0
+
| ||[[Metronidazole]]||0
 
|-
 
|-
 
| ||Quinupristin dalfoppristin||+
 
| ||Quinupristin dalfoppristin||+

Revision as of 07:23, 4 March 2014

Background

Antibiotic Sensitivities[1]

Organisms ' Strep, Group A, B, C, G
Penicillins Penicillin G +
Penicillin V +
Anti-Staphylocccal Penicillins Methicillin +
Nafcillin/Oxacillin +
Cloxacillin/Diclox. +
Amino-Penicillins AMP/Amox +
Amox/Clav +
AMP-Sulb +
Anti-Pseudomonal Penicillins Ticarcillin +
Ticar-Clav +
Pip-Taxo +
Carbapenems Piperacillin +
Doripenem +
Ertapenem +
Imipenem +
Meropenem +
[[Aztreonam[[ 0
Fluroquinolones Ciprofloxacin +/-
Ofloxacin +/-
Pefloxacin 0
Levofloxacin +
Moxifloxacin +
Gemifloxacin +
Gatifloxacin +
1st G Cephalo Cefazolin +
2nd G. Ceph Cefotetan +
Cefoxitin +
Cefuroxime +
3rd/4th G. Ceph Cefotaxime +
Cefizoxime +
CefTRIAXone +
Ceftobiprole +
Ceftaroline +
CefTAZidime +
Cefepime +
1st G. Ceph Cefadroxil +
Cephalexin +
2nd G. Ceph Cefaclor/Loracarbef +
Cefproxil +
Cefuroxime axetil +
3rd G. Ceph Cefixime +
Ceftibuten +
Cefpodox/Cefdinir/Cefditoren +
Aminoglycosides Gentamicin 0
Tobramycin 0
Amikacin 0
Chloramphenicol +
Clindamycin +
Macrolides Erythromycin +/-
Azithromycin +/-
Clarithromycin +/-
Ketolide Telithromycin +
Tetracyclines Doxycycline +/-
Minocycline +
Glycylcycline Tigecycline +
Glyco/Lipoclycopeptides Vancomycin +
Teicoplanin +
Telavancin +
Fusidic Acid +/-
Trimethoprim +
TMP-SMX +
Urinary Agents Nitrofurantoin +
Fosfomycin
Other Rifampin +
Metronidazole 0
Quinupristin dalfoppristin +
Linezolid +
Daptomycin +
Colistimethate 0

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

Table Overview

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2010